A01 AC-05 is capable of inducing expression of proteins related to apoptosis pathways in melanoma cells Michelly Cristiny Pereira. UFPE - Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil.

A02 Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression Ulises Daniel Orlando. Biomedical Research Institute, INBIOMED (UBA, CONICET), Department of Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires, Buenos Aires, Argentina.


A04 Analysis of the interaction and sub-localization of the HSP70 protein and its co-chaperones in tumor cells Sofia Scomazzon. PUCRS, Porto Alegre, RS, Brazil.

A05 Antitumoral effect of the co-chaperone HspBP1 Karina Lima. PUCRS, Porto Alegre, Rio Grande do Sul, Brazil.

A06 Autophagic and endocytic vesicular traffic role of WNK2 in glioma Ana Laura Vieira Alves. Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

A07 Bioinformatics and immunohistochemical analyses reveal a possible risk biomarker for developing gastric cancer Ivaine Sartor. UFRGS, Porto Alegre, RS, Brazil.

A08 Biomarkers of early-stage recurrence in endometrial cancer. Identification studies using bioinformatics tools and molecular approaches. María José Besso. Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME), Buenos Aires, Provincia de Buenos Aires, Argentina.

A09 Characterization of a melanoma cell culture on a new three-dimensional scaffold model Julia Crispim da Fontoura. PUCRS, Porto Alegre, RS, Brazil.

A10 Clinicopathological and Sociodemographic Data Collection from Non-Small Lung Cancer Patients for Research on Genomic Field and Inclusion in Internacional Consortia Leticia Ferro Leal. Barretos Hospital Cancer, Barretos, São Paulo, Brazil.


A12 Comparison of NGS and ddPCR for detecting point mutations and genomic rearrangements in circulating tumor DNA Isabella Meira. A.C. Camargo, Sao Paulo, SP, Brazil.
A13 Complete tumor inhibition upon treatment of a human melanoma cell line with adenovirus-mediated interferon-beta gene therapy. Otto Cerqueira. ICESP, São Paulo, SP, Brazil.

A14 Comprehensive molecular profiling of murine melanoma progression identifies independent prognostic factors for melanoma patients Miriam Jasiulionis. UNIFESP, São Paulo, SP, Brazil.

A15 Co-treatment of lung tumor cells with Adp53 and CDK4/6 inhibitor Palbociclib: A multipronged approach to reach both Rb and p53 pathways Ana Dias. University of Sao Paulo, Biomedical Science Institute, Sao Paulo, Sao Paulo, Brazil.

A16 Dendritic cells as powerful tools to detect T cell responses against tumor cells Mariana Pinho. Institute of Biomedical Sciences of the University of Sao Paulo, Sao Paulo, SP, Brazil.

A17 Drinking for the liver?: experimental evidence on the attenuation of fibrosis-associated hepatocarcinogenesis by the combination of bioactive coffee compounds Guilherme Romualdo. UNESP - São Paulo State University, Botucatu Medical School, Department of Pathology, Botucatu, São Paulo, Brazil.

A18 Effect of bone cells HO-1 ablation in the communication between prostate cancer cells and bone progenitors Nicolas Anselmino. IQUIBICEN-Buenos Aires Univ., Buenos Alres, CABA, Argentina.

A19 Establishment of canine melanoma cell lines, molecular characterization and development of a model of cancer gene therapy Otávio Rodrigues. Instituto do Câncer do Estado de São Paulo (ICESP)-Faculdade de Medicina da USP (FMUSP), São Paulo, São Paulo, Brazil.

A20 ET<sub>A</sub>R expression and activation is related to the steroidogenic pathways in the progression of prostate cancer Marí José Torres. University of Chile, Santiago, Chile.

A21 Evaluation of the expression and therapeutic potential of toxins present in the snake venom *Bothrops jararaca* Elisa Messias. Barretos Cancer Hospital, Barretos, SP, Brazil.

A22 Exome sequencing of germline DNA from non-*BRCA1/*BRCA2* carriers of Brazilian families at high-risk for hereditary breast/ovarian cancer Paula Felicio. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.

A23 Generation of a Pcyt2 knockout lung cancer cell line using CRISPR-Cas9 as a new target validation approach Sarah Teixeira. Institute of Biomedical Sciences/USP, São Paulo, SP, Brazil.

A24 Genomic landscape of Brazilian non-small cell lung cancer Leticia Ferro Leal. Barretos Cancer Hospital, Barretos, SP, Brazil.

A26 Immune landscape in esophageal squamous cell cancer Luciana Barros. INCA, Rio de Janeiro, Rio de Janeiro, Brazil.

A28 **Immunological landscape in metastatic versus non-metastatic oral cavity tumors** Marco Pretti. Instituto Nacional de Câncer, Rio de Janeiro, Rio de Janeiro, Brazil.

A29 **Influence of BRCA1 germline mutations in the somatic mutational burden of triple-negative breast cancer** Rafael Brianese. A. C. Camargo Cancer Center, São Paulo, SP, Brazil.

A30 **Influence of claudin-3 in the response to ionizing radiation in colorectal cancer cells** Perôny Nogueira. Brazilian National Cancer Institution, Rio de Janeiro, RJ, Brazil.

A31 **Investigating galectin-7 in pancreatic cancer: Tissue expression, serum levels and biological implication** Antônio Silva-Filho. UFPE, Recife, PE, Brazil.

A32 **Investigation of FAK signaling in the epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in colorectal cancer** Pedro Barcellos-de-Souza. Cellular Structural and Dynamics Group, Molecular and Cellular Oncobiology Program, Brazilian National Cancer Institute - INCA, Rio de Janeiro, RJ, Brazil.

A33 **Long non-coding RNA in cis regulation of protein coding genes reveals novel pathways involved in Ewing sarcoma metastasis** Rafael Coan. UNESP, Botucatu, SP, Brazil.

A34 **Mass spectrometry-based proteomics of the invasive tumor front and matched lymph node metastasis in head and neck squamous cell carcinoma** Ariane Busso-Lopes. Brazilian Biosciences National Laboratory - LNBio, Brazilian Center for Research in Energy and Materials - CNPEM, Campinas, SP, Brazil.

A35 **Mass spectrometry-based proteomics study makes YWHAZ a potential prognosis biomarker for prostate cancer, independent from Gleason score** Juan Bizzotto. Department of Biological Chemistry, FCEN, University of Buenos Aires, IQUIBICEN-CONICET, CABA, Buenos Aires, Argentina.


A37 **Melanoma microenvironment has a potential therapeutic target by Interferon beta gene therapy** Igor Vieira. ICESSP - FMUSP, São Paulo, São Paulo, Brazil.

A38 **Molecular cloning of four genes derived from Ectatomma opaciventre (arthropod) venom gland, with therapeutic potential for treatment of head and neck tumors** Ângela Oliveira. Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
A39 Molecular profile for cetuximab resistance in head and neck cancer cell lines Izabela Natalia Faria Gomes. Barretos Cancer Hospital, Barretos, SP, Brazil.

A40 MTAP (Methylthioadenosine Phosphorylase) expression is frequently reduced in high grade gliomas Weder Menezes. Barretos Cancer hospital, Barretos, São Paulo, Brazil.

A41 Murine breast tumors induce systemic alterations of the B cell compartment Nicolás Sarbia. Instituto de Biología y Medicina Experimental (IBYME), Ciudad de Buenos Aires, Argentina.

A42 Mutation signature is bladder cancer is PolQ dependent Tirzah Braz Petta Lajus. UFRN, Natal, RN, Brazil.

A43 Novel synthetic naphthoquinone-derived compounds can inhibit cell viability by blocking cell cycle progression and inducing cell death in metastatic prostate cancer cell lines Paula Priscilla de Freitas dos Santos. INCA, Rio de Janeiro, RJ, Brazil.

A44 OPNa splice variant overexpression is associated with matrix calcification and collagen deposition in thyroid cancer cell lines Luciana Ferreira. Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.

A45 P53 and interferon beta as a combined strategy for colorectal cancer gene therapy Paulo R Del Valle. ICESP, São Paulo, SP, Brazil.

A46 Pancreatic Adenocarcinoma and Translational control of the module IMPACT/GCN1/GCN2 Fernanda Ferreira. A.C.Camargo Cancer Center, São paulo, São Paulo, Brazil.

A47 Radiosensitization of colorectal tumors: addition of metformin to neoadjuvant treatment Paula Asprino. Hospital Sírio-Libanês, Sao Paulo, SP, Brasil.

A48 Role of aerobic exercise training on tumor-infiltrating immune cells Vanessa Voltarelli. Sírio Libanês Hospital, São Paulo, SP, Brazil.

A49 Role of cofilin-1 during epithelial-mesenchymal transition in colorectal cancer cells Annie Squiavinato. Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.

A50 Searching for new predictive biomarkers of immunotherapy in lung adenocarcinoma: exploring data from TCGA in hypermutated tumors Ivaine Sartor. PPGBM-UFRGS, Porto Alegre, RS, Brazil.

A51 Serum levels of melatonin in patients with hepatocarcinoma and prostate cancer Debora Zuccari. Faculdade de Medicina de São José do Rio Preto - FAMERP, São José do Rio Preto, São Paulo, Brazil.

A52 SPARC induces epithelial-mesenchymal transition in prostate cancer cells through an Integrin avb3 / ZEB1 signaling pathway Fernanda López-Moncada. Universidad de Chile, Santiago, Chile.
A53  **Sputum as a novel approach for the detection of driver mutations in patients with non-small cell lung cancer: a preliminary study** vanessa de Sá. Ac Camargo Cancer Center, São Paulo, São Paulo, Brasil.

A54  **STMN3 expression level differentiate low grade oligodendroglioma from astrocytoma.** Fernanda Serachi. Universidade de São Paulo, São Paulo, São Paulo, Brazil.

A56  **T Follicular helper cells expansion during colon and mammary tumor development** Montana Manselle Cocco. Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), CONICET, Ciudad de Buenos Aires, Argentina.

A57  **The functional role of LOXL3 in astrocytomas** Talita Laurentino. Universidade de São Paulo, São Paulo, São Paulo, Brazil.

A58  **The LQB-223 compound exhibits antitumor activity against breast cancer cells with distinct phenotypes** Lauana Lemos. Instituto Nacional de Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.

A59  **The radiosensitizing effect and immune-modulatory function of PI4K IIIα inhibition using anti-hepatitis C viral agent in breast cancer model: a potential model of drug repositioning** In Ah Kim. Seoul National University, College of Medicine, Seoul, South Korea.

A61  **The role of the miR-143/miR-145 cluster in chondrosarcoma progression** Joaquin Urdinez. Balgrist University Hospital/ ETH Zurich, Zurich, Zurich, Switzerland.

A62  **Therapeutic effect of LQB-118 and LQB-223 compounds against subcutaneous xenograft model of glioblastoma** Gustavo Guimarães. The Brazilian National Cancer Institute, Rio de Janeiro, RJ, Brazil.

A63  **Transcriptomics analysis of horse melanoma tumors treated with amblyomin-X suggests an apoptotical versus survival duel, er-stress, and immunogenic cell death responses: a translational study** Flavio Lichtenstein. Butantan Institute, Sao Paulo, SP, Brazil.

A64  **Use of shRNA screen to identify ubiquitin related genes involved in the regulation of tumor-cell migration and invasion.** Fabiana Rossi. Biomedicine Research Institute of Buenos Aires, CABA, Buenos Aires, Argentina.

A65  **BET and mTOR inhibitors combination is associated with differential gene expression in acute myeloid leukemia** Mariane T Amano. Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil.

A66  **CAR T cells generated using Sleeping Beauty transposon vectors and expanded with a lymphoblastoid cell line (LCL) have antitumor activity in vitro and in vivo.** Leonardo Chicaybam. FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil.

A68 CRLF2 expression associates with combined \(<i>NOTCH1/IKZF1</i>\) status in childhood T-cell acute lymphoblastic leukaemia Ana Luiza Maciel. Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.

A70 Extracellular vesicles size and concentration as diagnostic marker for canine multicentric lymphoma Taismara Garnica. University of Sao Paulo, Pirassununga, Sao Paulo, Brazil.

A71 Genomic profile of \(<i>RUNX1-ETV6</i>\)+ pediatric B-cell precursor acute lymphoblastic leukemia Thayana Barbosa. Molecular Cancer Study Group, Division of Clinical Research, Research Centre, Instituto Nacional de Câncer - INCA, Rio de Janeiro, Rio de Janeiro, Brazil.
